Gain Therapeutics Q1 net loss $0.22/shr; cash $12.7M; GT-02287 Phase 1 SAD positive

Gain Therapeutics, Inc.

2024-Q1 EPS reported -$0.22

GAAP net loss per share $0.22 (Q1 2024) vs $0.43 (Q1 2023); narrower loss.
Cash, equivalents & marketable securities $12.7M as of March 31, 2024; cash runway guided into 2025.
R&D expenses $2.5M (down from $2.8M YoY); G&A expenses $1.9M (down from $2.5M YoY).
Positive SAD data for GT-02287; MAD part of Phase 1 initiated for GBA1 Parkinson’s disease.
Appointed Gene Mack as CFO and Jonas Hannestad, M.D., Ph.D. as CMO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.